Sudarshan Pharma Industries Share Price

Sudarshan Pharma Industries Limited was initially incorporated as a Private Limited Company with the name Sudarshan Specialty Chemsolve Private Limited on July 23, 2008 with the Registrar of Companies, Mumbai. Later in year 2016. name of the Company changed from Sudarshan Specialty Chemsolve Private Limited to Sudarshan Pharma Industries Private Limited on 17 December 2016. Thereafter, the Company converted into a Public Limited and name of the Company was changed to Sudarshan Pharma Industries Limited on January 5, 2017. The Company was promoted by Mr. Hemal V. Mehta Mr. Sachin V. Mehta, who have a combined experience of over 25 years in the Special Chemical, Bulk drug and Pharmaceutical Industry. At present, Company perates in pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. It exports primarily to South East Asia, Middle East, and North Africa. The Companys services include contract manufacturing and supplying generic pharmaceutical formulations to healthcare institutions through its distribution network.The Company outsources its manufacturing facility, deal in Import and Exports, indenting and Supply in Specialty chemicals, API its intermediate. As per the clients need and requirement, the company provides order and get them manufactured from various suppliers in India and abroad regularly. Specialty chemicals and Intermediates having wide application in pharma, paint, food and adhesive Industry. It is also involved in Contract Manufacturing, outsource Supply of Generic Pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals. It also offer services of QC and Formulation Development to provide customised solutions to our customers and assist them in sourcing the innovative products as per their needs. The Company carries about Ethical marketing of Pharmaceutical formulation products in the Domestic and International market through distribution network and Sales force under its own brand. Presently, the Company has joined hands with regular suppliers having FDA and WHO approved plant along with their own unit to supply pharma formulation and more than 100 generic pharma products. These units manufacture tablets, capsules, dry powder, dry injections powder, liquids, Injections dry injections for their own brands.Apart from these, the Company has launched wide products range in pharma formulation such as Setdown, Pulmo relief, Fix Pollen, Flupimac and has established goodwill for quality products and have regular clients for the same. Further, it supplies generic pharmaceutical formulation as Make to order for bulk supply to the hospital, Health Centre of Corporate, Municipality and exports.The Company operate both in domestic and international markets. Presently, it is supplying Active Pharmaceutical Ingredients(APIs), Intermediates Finished Dosage Formulations (FDFs) and Specialty Chemicals (SCs) in the domestic markets. It has entered into MOU / Agreements with Storage Houses / Warehouses facility providers at Bhiwandi Thane, Maharashtra, Wada Palghar, Maharashtra and Baddi, Himachal Pradesh for using their premises for the stock keeping of the products. The Company has also entered into Lease Agreement with Group Company, Sudarshan Chempharm LLP for using its premises and land to set up proposed Manufacturing and Storage / Warehouse Facility at Wada, in Maharashtra.In domestic pharmaceuticals markets, currently, the Company has good presence and is servicing through a Supply Chain Network of Consignee Agents with products range. It also provide onsite support assistance to clients using their Drug Intermediates and Specialty Chemicals.The Company launched the Initial Public Offer by issuing 68,62,400 Equity Shares having the face value of Rs 10 each by raising funds aggregating to Rs. 50 Crore, via fresh issue in March, 2023.Ratna Lifesciences Private Limited was incorporated as a wholly owned subsidiary company on November 10, 2023. Life Science Chemical Private Limited was incorporated on August 23, 2023.In FY 202425, Company achieved development of the molecule VITAMIN B6 (Pyridoxine Hydrochloride) from base root till the finished product and also manufactured all the intermediary products required to manufacture the finished API products of VITAMIN B6. It also achieved first milestone in developing the sample for the molecule VITAMIN B1 (Thiamine Hydrochloride) from Base Root for Manufacturing Process of VITAMIN B1.

Sudarshan Pharma Industries reported a Q2 FY2025–2026 revenue of ₹145.26 crore, up 8.9% YoY, with net profit increased 39.2% to ₹3.96 crore. For the full year FY2025–2026, revenue reached ₹507.57 crore and profit touched at ₹15.95 crore. As of Jun '25, Sudarshan Pharma Industries’s market capitalisation stood at ₹791.05 crores. Shareholding as of Jun '25 shows promoters holding 57.4%, with FIIs at 19.5%, DIIs at %, and public at %.

As of 19 Aug, 2025, Sudarshan Pharma Industries share price is ₹32.9. The stock opened at ₹33 and had closed at ₹32 the previous day. During today’s trading session, Sudarshan Pharma Industries share price moved between ₹31.98 and ₹32.98, with an average price for the day of ₹32.48. Over the last 52 weeks, the stock has recorded a low of ₹15.51 and a high of ₹53.50. In terms of performance, Sudarshan Pharma Industries share price has declined by 2.2% over the past six months and has increased by 81.81% over the last year.